2016-03-12T00:00:00.000-05:00
Sucampo Pharmaceuticals,0.0116282
Pharmaceuticals’s revenue,-0.418304
52-week low,-0.735449
price target,0.441101
global biopharmaceutical company,0.202818
Acadian Asset Management,0.537542
recent quarter,0.537542
midday trading,-0.305927
consensus price target,0.441101
52-week high,-0.735449
related companies,0.560435
InvestorPlace Broker Center,0.555736
high fees,-0.735674
biopharmaceutical company,0.202818
Zacks Investment Research,0.478091
personal trading style,0.598412
recent disclosure,0.420111
strong sell,0.314216
Roth Capital,0.305711
average rating,-0.233336
clinical development activities,0.269857
research offerings,0.40995
analyst M. Higgins,0.305711
average price,0.406756
consensus estimate,0.327717
Sucampo Pharmaceuticals Inc.,0.560435
shares,-0.305927
concise daily summary,0.448938
stock broker,0.245696
oncology-based inflammatory disorders,-0.666989
rating,-0.233336
